Opiate Dependence Agents

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	**DD** – Drug-Drug Interaction	**MD** – Maximum Dose Limit	**TD -** Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	**DS** – Maximum Days' Supply Allowed	**PR** – Enrollment in a Physician-Supervised Program Required	**UN** – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	**DT** – Duration of Therapy Limit	**PU** – Prior Use of Other Medication is Required	**X** – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	**DX** – Diagnosis Code Requirement	**QL** – Quantity Limit	**YQ** – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	**ER** – Early Refill	**RX** – Specific Prescription Requirement	

Opiate Dependence Agents

<table>
<tr><th colspan="3">POS Edits</th></tr>
<tr><td rowspan="8">AL – The agents listed in the table to the right are limited to use in recipients who meet specific age requirements.</td><td colspan="2">Minimum Age Requirements</td></tr>
<tr><td>Generic (Brand Example)</td><td>Minimum Age</td></tr>
<tr><td>Buprenorphine (Sublocade®)</td><td>18 years</td></tr>
<tr><td>Buprenorphine SL</td><td>16 years</td></tr>
<tr><td>Buprenorphine/Naloxone (Suboxone®, Zubsolv®)</td><td>16 years</td></tr>
<tr><td>Lofexidine (Lucemyra®)</td><td>18 years</td></tr>
<tr><td>Naltrexone Extended-Release Injectable Suspension (Vivitrol®)</td><td>18 years</td></tr>
<tr><td>Naltrexone Tablet</td><td>18 years</td></tr>
<tr><td colspan="3">CU – These agents are monitored at POS for concurrent use with other agents.
- Incoming pharmacy claims for a buprenorphine-containing agent used for opiate dependence will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid analgesic.</td></tr>
<tr><td colspan="3">DD – Pharmacy claims for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) will deny for drug-drug interaction when the recipient has an active prescription (a prescription in which the days' supply has not expired) for any opioid (including buprenorphine-containing products) and vice versa.</td></tr>
<tr><td colspan="3">DS – Pharmacy claims for lofexidine tablets are limited to a 14-day supply per 6-month period.</td></tr>
<tr><td colspan="3">DX – Pharmacy claims for some agents must be submitted with an appropriate diagnosis code.
- Pharmacy claims for all buprenorphine opiate dependence agents (single-ingredient and combination) must be submitted with a diagnosis code for opioid dependence (F11.2*).
- Pharmacy claims for lofexidine (Lucemyra®) must be submitted with a diagnosis code for ONE of the following:
o Opioid abuse with withdrawal – F11.13
o Opioid dependence with withdrawal – F11.23
o Opioid use, unspecified with withdrawal – F11.93
- Pharmacy claims for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) must be submitted with either a diagnosis code for opioid dependence (F11.2*) or alcohol dependence (F10.2*).
* Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code</td></tr>
<tr><td colspan="3">MD – The following agents are limited to a maximum daily dose:
- Buprenorphine agents (single-ingredient and combination) are limited to a maximum daily dose of 24mg per day of buprenorphine or buprenorphine equivalent. Refer to specific product prescribing information for buprenorphine equivalence charts.
- Lofexidine 0.18mg tablet is limited to a maximum daily dose of 2.88mg (16 tablets).</td></tr>
</table>

Opiate Dependence Agents

POS Edits		
QL – Some agents have quantity limits as listed in the chart to the right.	**Quantity Limits**	
	Generic (Brand Example)	**Quantity Limit**
	Buprenorphine Extended-Release Injection (Sublocade®)	1 unit/26 days
	Buprenorphine SL Tablet 2mg	2 units/day
	Buprenorphine SL Tablet 8mg	3 units/day
	Buprenorphine/Naloxone 2mg/0.5mg SL Tab (Suboxone®)	2 units/day
	Buprenorphine/Naloxone 2mg/0.5mg SL Film (Suboxone®)	1 unit/day
	Buprenorphine/Naloxone 4mg/1mg SL Film (Suboxone®)	1 unit/day
	Buprenorphine/Naloxone 8mg/2mg SL Film/Tab (Suboxone®)	3 units/day
	Buprenorphine/Naloxone 12mg/3mg SL Film (Suboxone®)	2 units/day
	Buprenorphine/Naloxone SL Tablet 0.7mg/0.18mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 1.4mg/0.36mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 2.9mg/0.71mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 5.7mg/1.4mg (Zubsolv®)	3 units/day
	Buprenorphine/Naloxone SL Tablet 8.6mg/2.1mg (Zubsolv®)	2 units/day
	Buprenorphine/Naloxone SL Tablet 11.4mg/2.9mg (Zubsolv®)	1 unit/day
	Naltrexone Extended-Release Injectable Suspension (Vivitrol®)	1 unit/28 days
	Naloxone Nasal Spray (Narcan®)	4 units/30 days
	Naloxone Nasal Spray (Kloxxado™)	4 units/30 days
	Naloxone Injectable Solution/Cartridge 0.4mg/ml	4 units/30 days
	Naloxone Injectable Solution Syringe 1mg/ml	4 units/30 days
	Naloxone Injectable Solution (5ml, 10ml, 20ml) 1mg/ml	1 unit/30 days
	Naloxone Injectable Solution (10ml) 0.4mg/ml	1 unit/30 days
	Naloxone Injectable Solution (Zimhi™)	4 syringes (2ml)/30 days
TD – These agents are monitored at the pharmacy POS for duplication of therapy with each other. - Incoming prescriptions for buprenorphine or buprenorphine/naloxone agents will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for any buprenorphine or buprenorphine/naloxone agent. - Incoming prescriptions for any naltrexone agent will deny when the recipient has an active prescription for any other naltrexone agent.		
~~**X** – Prescribers of buprenorphine must meet enrollment and certification requirements.~~		

Opiate Dependence Agents

POS Edits	
Revision / Date	**Implementation Date**
Created POS Document	February 2020
Updated age for BH in POS Abbreviations chart / November 2020	January 2021
Added POS edits for lofexidine and naltrexone / January 2021	April 2021
Modified quantity limit for Sublocade® / May 2022	June 2022
Modified wording for concurrent use with buprenorphine-containing products, Clarified DD for naltrexone / February 2022	July 2022
Added Kloxxado™ and Zimhi™ and policy clarifications / April 2022	October 2022
Modified quantity limit for naloxone agents / Sept 2022	January 2023
Removed 'X' DEA number wording / January 2023	April 2023